IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on gamma-delta (γδ) T cell therapies, has unveiled promising preclinical data for its γδ T cell engager, INB-619, at the 2025 American College of Rheumatology (ACR) Convergence Meeting in Chicago. The data indicate that INB-619 can achieve complete B cell elimination in preclinical models of systemic lupus erythematosus (SLE), matching the efficacy of existing CD19 and CD20 engagers while exhibiting a significantly lower risk of adverse cytokine release.
This development is particularly relevant as current T cell engagers often trigger toxicities, including cytokine release syndrome (CRS). INB-619’s unique mechanism, which bypasses CD3 engagement, suggests a transformative approach to treating autoimmune diseases by reducing the likelihood of severe side effects. The ability to achieve deep B cell depletion without activating conventional T cells may enhance safety and tolerability, positioning INB-619 as a potential first-in-class therapy.
As IN8bio advances its γδ T cell platform, the implications for autoimmune disease management could be substantial. By effectively targeting and depleting pathogenic B cells while preserving healthy immune function, INB-619 may offer a novel solution for patients suffering from B cell-driven disorders like SLE. This innovative approach underscores IN8bio’s commitment to addressing unmet medical needs in both oncology and autoimmune indications, potentially reshaping treatment paradigms in these challenging therapeutic areas.
Start your 7-day trial and see what the database can do →
